Pharma Giant Gilead Retracts Request FDA Extend Monopoly Status on Experimental Covid-19 Drug
Pharmaceutical giant Gilead Sciences on Wednesday retracted its effort to score extended monopoly rights and tax breaks on its antiviral drug remdesivir, which scientists are evaluating as a possible treatment in the novel coronavirus pandemic.